[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647779":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":87,"collaborators":11,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":11,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":11,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":116,"whyStopped":11,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Treeline Biosciences, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 Dose Escalation and Part 2 Dose Expansion","EXPERIMENTAL",null,[13,14],"Drug: TLN-499","Drug: Venetoclax",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","TLN-499","Specified dose on specified days",[9],{"type":17,"name":22,"description":19,"armGroupLabels":23,"otherNames":11},"Venetoclax",[9],[25],{"name":26,"affiliation":5,"role":27},"Padma Yerramilli-Rao, MB BS, PhD","STUDY_CHAIR",[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Treeline Clinical Operations","CONTACT","857-228-0050","clinicaloperations@treeline.bio",[35,55,71],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"COBL Clinical Trials - Chris O'Brien Lifehouse","Camperdown","New South Wales","2050","Australia","AU",{"type":43,"coordinates":44},"Point",[45,46],151.17642,-33.88965,{"lat":46,"lon":45},[49,53],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},"Steven Kao","+61 (2) 8514 0594","Steven.kao@lh.org.au",{"name":50,"role":54,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":56,"status":11,"city":57,"state":58,"zip":59,"country":40,"countryCode":41,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Cabrini Hospital Malvern","Malvern","Victoria","3144",{"type":43,"coordinates":61},[62,63],145.02811,-37.86259,{"lat":63,"lon":62},[66,70],{"name":67,"role":31,"phone":68,"phoneExt":11,"email":69},"Surein Arulananda","+61 (3) 9496 3088","surein.arulananda@austin.org.au",{"name":67,"role":54,"phone":11,"phoneExt":11,"email":11},{"facility":72,"status":11,"city":73,"state":74,"zip":75,"country":40,"countryCode":41,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Linear Clinical Research","Nedlands","Western Australia","6009",{"type":43,"coordinates":77},[78,79],115.8073,-31.98184,{"lat":79,"lon":78},[82,86],{"name":83,"role":31,"phone":84,"phoneExt":11,"email":85},"Timothy Humphries","+61 (08) 6382 5100","thumphries@linear.org.au",{"name":83,"role":54,"phone":11,"phoneExt":11,"email":11},{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100647779","phase-1-tln-499-in-combination-with-venetoclax-in-patients-with-relapsedrefractory-solid-tumors-100647779",false,"NCT07713732","TLN-499 in Combination With Venetoclax in Patients With Relapsed\u002FRefractory Solid Tumors","An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed\u002FRefractory Solid Tumors","Inclusion Criteria:\n\n1. Adults ≥18 years of age\n2. Histologically confirmed relapsed\u002Frefractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma\n3. Measurable disease per RECIST v1.1 or mRECIST\n4. ECOG performance status 0-1\n5. Adequate hematologic, hepatic, renal, and coagulation function.\n6. Life expectancy ≥12 weeks\n7. Signed informed consent\n\nExclusion Criteria:\n\n1. Active brain metastases\n2. Major surgery or severe trauma within 4 weeks before first dose\n3. Significant uncontrolled medical conditions preventing study participation\n4. Use of prohibited concomitant medications\n5. Previous conditions that would interfere with study assessments or safety","ALL","18 Years",{"count":99,"type":100},120,"ESTIMATED","INTERVENTIONAL",[103],"PHASE1","The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed\u002Frefractory solid tumors.",[106,107,108,109],"Small Cell Lung Cancer ( SCLC )","Neuroendocrine Cancer","Malignant Pleural Mesotheliomas (Mpm)","Synovial Sarcomas",[18,22,111,112,107,113,114,115],"Relapsed\u002FRefractory Solid Tumors","Small Cell Lung Cancer","Malignant Pleural Mesothelioma","Synovial Sarcoma","Phase 1","NOT_YET_RECRUITING","2026-07-27",{"date":119,"type":120},"2026-07-28","ACTUAL",{"date":122,"type":100},"2026-07-25",{"date":124,"type":100},"2030-08-29",{"name":5,"class":6},3]